ICU MEDICAL INC/DE

ICUI

ICU MEDICAL INC/DE

ICUI

Insider Sentiment (TTM):

Last Purchase:2025-08-27Last Sale:2026-05-22Shares Purchased (TTM):1,200Shares Sold (TTM):12,106

Institutional Sentiment:

As of:2026-03-31Institutional Shares Owned:23,905,549Shares Outstanding:24,764,000Institutional Ownership Pct.:96.53%

Earnings Market Reaction:

Filing Date:2026-08-06Price on Filing Date:N/APrevious Close:N/A% Change:N/A

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Financial Statements

10‑Q10‑K

Values in Millions ($)	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30
Assets
Cash And Cash Equivalents At Carrying Value	298	288	308	300	300	290	309	313	303	251	254	197
Available For Sale Securities Debt Securities Curr…	-	-	-	-	-	-	0	0	0	0	1	2
Accounts Receivable Net Current	184	201	181	192	179	171	183	174	152	145	162	162
Cash Cash Equivalents And Short Term Investments	-	-	-	-	-	-	309	313	303	251	255	199
Inventory Net	607	606	616	622	616	590	585	692	683	693	709	760
Prepaid Expense And Other Assets Current	122	118	86	94	84	75	82	74	81	83	74	84
Assets Current	1,211	1,213	1,191	1,207	1,180	1,424	1,442	1,258	1,236	1,188	1,221	1,219
Prepaid Taxes	-	-	17	-	-	11	11	6	18	15	22	15
Assets Of Disposal Group Including Discontinued Op…	-	5	0	0	0	0	284	-	-	-	0	-
Property Plant And Equipment Net	447	445	452	456	452	442	443	596	594	603	613	609
Available For Sale Securities Debt Securities Nonc…	-	-	-	-	-	-	-	-	-	-	0	0
Operating Lease Right Of Use Asset	39	51	54	57	59	58	53	60	66	65	70	74
Goodwill	1,484	1,486	1,500	1,499	1,502	1,455	1,433	1,478	1,451	1,459	1,472	1,444
Intangible Assets Net Excluding Goodwill	568	599	634	665	698	717	741	786	806	837	871	891
Deferred Income Tax Assets Net	26	26	26	24	23	24	24	41	39	40	37	31
Other Assets Noncurrent	63	63	63	61	61	65	65	87	95	97	94	108
Equity Method Investments	134	131	132	134	132	-	3	-	-	-	-	-
Assets	3,971	4,014	4,051	4,103	4,107	4,185	4,204	4,305	4,287	4,288	4,378	4,377
Liabilities And Stockhold…
Liabilities Current
Accounts Payable Current	149	174	154	172	169	180	148	169	156	152	150	149
Accrued Liabilities Current	322	315	315	316	314	279	307	326	300	248	268	251
Long Term Debt Current	19	19	19	0	0	48	51	51	51	51	51	46
Accrued Income Taxes Current	8	11	10	5	0	12	17	3	4	2	8	11
Liabilities Of Disposal Group Including Discontinu…	-	-	0	0	0	30	33	-	-	-	0	-
Liabilities Current	498	518	499	493	483	549	556	550	512	455	482	464
Secured Long Term Debt	-	-	1,266	-	-	-	1,532	-	-	-	1,578	-
Business Combination Contingent Consideration Liab…	-	-	-	-	-	-	0	2	2	2	5	6
Other Accrued Liabilities Noncurrent	-	-	90	-	-	-	67	-	-	-	-	-
Long Term Debt Noncurrent	1,212	1,262	-	1,314	1,338	1,489	-	1,543	1,555	1,566	-	1,589
Other Liabilities Noncurrent	71	82	-	94	96	78	-	80	91	103	-	100
Deferred Income Tax Liabilities Net	12	15	38	41	43	45	49	49	54	56	56	78
Accrued Income Taxes Noncurrent	25	25	35	34	32	36	35	35	33	36	35	40
Business Combination Contingent Consideration Liab…	-	-	-	-	-	-	0	0	4	4	4	7
Commitments And Contingencies	-	-	0	-	-	-	0	-	0	0	0	0
Other Liabilities	-	-	-	-	-	-	67	-	-	-	100	-
Stockholders Equity Inclu…
Convertible Preferred Stock Nonredeemable Or Redee…	0	0	0	0	0	0	0	0	0	0	0	0
Common Stock Value	3	3	2	2	2	2	2	2	2	2	2	2
Additional Paid In Capital Common Stock	1,476	1,465	1,465	1,451	1,436	1,416	1,412	1,395	1,381	1,371	1,366	1,356
Treasury Stock Value	-23	-25	-0	-0	-0	-0	-0	-0	-1	-5	-0	-1
Retained Earnings Accumulated Deficit	740	721	691	707	710	675	690	714	747	768	808	825
Accumulated Other Comprehensive Income Loss Net Of…	-43	-52	-35	-33	-33	-105	-139	-62	-92	-70	-53	-85
Stockholders Equity	2,152	2,112	2,124	2,127	2,116	1,988	1,965	2,049	2,038	2,068	2,123	2,098
Liabilities And Stockholders Equity	3,971	4,014	4,051	4,103	4,107	4,185	4,204	4,305	4,287	4,288	4,378	4,377
Allowance For Doubtful Accounts Receivable Current	-	-	14	-	-	-	13	-	-	-	11	-
Allowance For Doubtful Accounts Receivable	14	15	-	13	14	13	-	10	12	12	-	11
Preferred Stock Par Or Stated Value Per Share	1	1	1	1	1	1	1	1	1	1	1	1
Preferred Stock Shares Authorized	1	1	1	1	1	1	1	1	1	1	1	1
Preferred Stock Shares Issued	0	0	-	0	0	0	-	0	0	0	-	0
Preferred Stock Shares Outstanding	0	0	0	0	0	0	0	0	0	0	0	0
Common Stock Par Or Stated Value Per Share	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1
Common Stock Shares Authorized	80	80	80	80	80	80	80	80	80	80	80	80
Common Stock Shares Issued	25	25	25	25	25	25	25	24	24	24	24	24
Shares Outstanding	25	25	25	25	25	25	25	24	24	24	24	24
Treasury Stock Common Shares	0	0	0	0	0	0	0	0	0	0	0	0

Subscribe to unlock 17+ years of financial data, unlimited metrics, and saved tables

Start 7-day free trial

Subscribe to unlock 17+ years of data, unlimited metrics, and saved tables

Start free trial

Custom Table

10‑Q10‑K

0/5

Search a metric to start building a table

Subscribe to unlock 17+ years of financial data, unlimited metrics, transformations, and saved visuals

Start 7-day free trial

Subscribe to unlock 17+ years of data, unlimited metrics, transformations, and saved visuals

Start free trial

Interactive Financial Visualizations

10‑Q10‑K

Stock Price:

OnOff

Transformations:

0/1

Search a metric to start building a visual

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Earnings Market Reaction

10‑Q10‑K

Fiscal Year	Q1 1 Month	Q1 2 Month	Q1 3 Month	Q2 1 Month	Q2 2 Month	Q2 3 Month	Q3 1 Month	Q3 2 Month	Q3 3 Month	Q4 1 Month	Q4 2 Month	Q4 3 Month
2026	10.01%	20.48%	27.93%	-	-	-	-	-	-	-	-	-
2025	-5.61%	-7.73%	-9.08%	-1.73%	-8.54%	-4.95%	14.48%	14.04%	17.74%	-15.95%	-16.07%	-15.57%
2024	4.49%	16.68%	25.80%	35.75%	43.25%	44.15%	-12.51%	-10.00%	-7.67%	-1.79%	-7.40%	-5.59%
2023	-	-	-	-15.50%	-30.58%	-41.92%	-10.45%	-2.22%	-6.26%	-8.15%	-10.34%	-2.64%
Earnings Market Reaction data beyond 3 years is for subscribers only. Unlock the full earnings market reaction history Start 7-day free trial

Subscribe to unlock 17+ years of financial data and 90+ calculated metrics

Start 7-day free trial

Subscribe to unlock 17+ years of data and 90+ calculated metrics

Start free trial

Performance and Valuation Metrics

Rows marked with a lock icon are subscribers only — subscribe to unlock 90+ calculated metrics and 17+ years of history.

Metrics	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30
Liquidity Ratios
Current Ratio	2.43	2.34	2.39	2.45	2.44	2.59	2.59	2.29	2.41	2.61	2.53	2.63
Quick Ratio	0.97	0.94	0.98	1.00	0.99	1.38	1.39	0.90	0.92	0.90	0.91	0.81
Working Capital	712.54M	695.34M	691.69M	714.39M	697.34M	874.89M	885.80M	708.50M	724.08M	732.37M	739.43M	755.37M
Leverage & Debt
Debt to Equity	0.23	0.25	0.23	0.23	0.23	0.28	0.28	0.27	0.25	0.22	0.23	0.22
Interest Coverage TTM	1.38	0.77	0.69	1.20	1.03	0.94	0.59	-0.10	0.11	0.04	0.32	0.49
Debt Ratio	0.13	0.13	0.12	0.12	0.12	0.13	0.13	0.13	0.12	0.11	0.11	0.11
Efficiency & Turnover
Asset Turnover TTM	0.53	0.53	0.54	0.55	0.57	0.57	0.56	0.54	0.53	0.52	0.51	0.51
Days Sales Outstanding TTM	30.68	31.48	29.72	28.75	25.48	23.84	26.39	26.19	24.87	23.01	30.96	30.40
Receivables Turnover TTM	11.90	11.60	12.28	12.70	14.32	15.31	13.83	13.94	14.68	15.86	11.79	12.01
Per Share Metrics
Diluted EPS TTM	1.20	1.84	0.03	-0.30	-1.50	-3.82	-4.83	-4.54	-2.90	-2.45	-1.23	-1.15
Free Cash Flow Per Share TTM	6.11	3.34	3.73	2.92	2.46	5.36	5.11	6.95	6.86	3.52	3.42	-0.10
Dividend Per Share TTM	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Margin Metrics
Gross Profit Margin TTM	39.13%	37.93%	36.84%	36.47%	35.84%	35.11%	34.62%	32.87%	32.47%	32.48%	32.75%	33.04%
Operating Profit Margin TTM	3.34%	2.02%	1.92%	3.23%	2.93%	2.75%	1.80%	-0.30%	0.33%	0.12%	1.01%	1.55%
Net Profit Margin TTM	1.39%	2.15%	0.03%	-0.32%	-1.56%	-3.87%	-4.94%	-4.74%	-3.07%	-2.63%	-1.31%	-1.25%
Growth Metrics
Net Revenue Growth (1Y)	-8.97%	-10.88%	-6.33%	-0.84%	2.96%	7.22%	5.44%	4.04%	0.46%	-2.10%	-0.92%	10.12%
Net Income Growth (1Y)	-181.43%	-149.46%	-100.62%	-93.37%	-47.80%	57.96%	296.86%	295.83%	45.98%	28.86%	-60.08%	-27.77%
EPS Growth (1Y)	-180.28%	-149.01%	-100.62%	-93.43%	-48.34%	55.92%	292.02%	290.88%	44.08%	27.75%	-60.45%	-28.44%
Valuation Metrics
P/E TTM	121.81	69.02	4,802.44	-402.25	-88.14	-36.37	-32.16	-40.12	-40.92	-43.83	-81.03	-102.41
P/B TTM	1.70	1.51	1.66	1.39	1.54	1.71	1.93	2.17	1.42	1.26	1.13	1.37
P/S TTM	1.70	1.48	1.58	1.28	1.37	1.41	1.59	1.90	1.26	1.15	1.06	1.28
Market Cap	3.67B	3.20B	3.52B	2.96B	3.26B	3.41B	3.78B	4.45B	2.90B	2.60B	2.40B	2.87B
Enterprise Value	4.60B	4.19B	4.49B	3.98B	4.29B	4.65B	5.06B	5.73B	4.20B	3.97B	3.78B	4.31B
Calculated Values
Free Cash Flow TTM	152.83M	82.71M	91.80M	71.96M	60.52M	131.49M	124.66M	169.88M	167.39M	85.14M	82.31M	-2.33M
Net Debt	932.90M	992.25M	976.70M	1.01B	1.04B	1.25B	1.27B	1.28B	1.30B	1.37B	1.37B	1.44B
Per-Share and Margin
EPS TTM
Adjusted EPS TTM
Cash Flow Per Share TTM
Pretax Margin TTM
Stock Comp to Revenue TTM
Turnover Ratios and Averages
Average Assets
Average Equity
Average Inventory
Average Receivables
Average Accounts Payables
Inventory Turnover TTM
Payables Turnover TTM
Days Inventory Outstanding TTM
Days Payables Outstanding TTM
Cash Conversion Cycle TTM
Working Capital to Revenue
Deferred Revenue to Revenue
Growth Rates
Total Assets Growth (1Y)
Total Assets Growth (3Y)
Total Assets Growth (5Y)
Dividends Paid Growth (1Y)
Dividends Paid Growth (3Y)
Dividends Paid Growth (5Y)
EPS Growth (3Y)
EPS Growth (5Y)
Net Income Growth (3Y)
Net Income Growth (5Y)
Net Profit Margin Growth (1Y)
Net Profit Margin Growth (3Y)
Net Profit Margin Growth (5Y)
Net Revenue Growth (3Y)
Net Revenue Growth (5Y)
Deferred Revenue Growth (1Y)
Retained Earnings Growth (1Y)
Credit, Liquidity, Returns, Payout
Cash Ratio
Net Working Capital
Debt to EBITDA TTM
Net Debt to EBITDA TTM
Net Debt to Equity
Altman A
Altman B
Altman C
Altman D
Altman E
Altman Z-Score
ROA TTM
ROE TTM
NOPAT TTM
ROIC TTM
Effective Tax Rate TTM
Payout Ratio TTM
Dilution Ratio
Retained Earnings to Equity
Treasury Stock to Equity
Treasury Stock Change (1Y)
Accrued to Current Liabilities
NCAV
NCAV Per Share TTM
Valuation Ratios
P/CF TTM
Dividend Yield TTM
Free Cash Flow Yield TTM
EV EBITDA TTM
EV EBIT TTM
Stock Compensation TTM
Adjusted Net Income TTM
Billings TTM
Total Debt
Invested Capital

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Insider Transactions

2026-05-22Sale

Owner: Woolson, Daniel

Title: President

Shares: 2,123

Price/Share: $132.21

Value: $280,681.83

Shares Owned: 22,479

Relationship: Officer

Ownership: Direct

2026-05-14Sale

Owner: Sanzone, Virginia Ruth

Title: VP, General Counsel

Shares: 2,447

Price/Share: $124.08

Value: $303,623.76

Shares Owned: 19,460

Relationship: Officer

Ownership: Direct

2026-05-12Sale

Owner: Greenberg, David C.

Title: -

Shares: 2,424

Price/Share: $122.91

Value: $297,933.84

Shares Owned: 7,960

Relationship: Director

Ownership: Direct

2025-11-25Sale

Owner: Woolson, Daniel

Title: VP, GM-Infusion Capital

Shares: 2,897

Price/Share: $152.35

Value: $441,357.95

Shares Owned: 11,297

Relationship: Officer

Ownership: Direct

2025-11-11Sale

Owner: Finney, Elisha W

Title: -

Shares: 1,285

Price/Share: $140.42

Value: $180,439.70

Shares Owned: 3,995

Relationship: Director

Ownership: Direct

Filed Date	Owner	Relationship	Title	Ownership	Purchase/Sale	No. Shares	Price Per Share	Value	Shares Owned	Document Type
2026-05-22	Woolson, Daniel	Officer	President	Direct	Sale	2,123	132.21	$280,681.83	22,479	4
2026-05-14	Sanzone, Virginia Ruth	Officer	VP, General Counsel	Direct	Sale	2,447	124.08	$303,623.76	19,460	4
2026-05-12	Greenberg, David C.	Director	-	Direct	Sale	2,424	122.91	$297,933.84	7,960	4
2025-11-25	Woolson, Daniel	Officer	VP, GM-Infusion Capital	Direct	Sale	2,897	152.35	$441,357.95	11,297	4
2025-11-11	Finney, Elisha W	Director	-	Direct	Sale	1,285	140.42	$180,439.70	3,995	4
2025-11-11	Sanzone, Virginia Ruth	Officer	VP, General Counsel	Direct	Sale	930	142.35	$132,385.50	5,456	4
2025-08-27	Greenberg, David C.	Director	-	Direct	Purchase	1,200	126.42	$151,704.00	7,960	4
2025-08-14	Jain, Vivek	Director,Officer	Chairman and CEO	Direct	Purchase	21,929	112.52	$2,467,451.08	130,149	4
2025-05-30	Sanzone, Virginia Ruth	Officer	VP, General Counsel	Direct	Sale	700	133.62	$93,534.00	6,386	4
2025-05-28	Voigtlander, Christian B.	Officer	Chief Operating Officer	Direct	Sale	4,985	128.50	$640,572.50	6,088	4
2025-05-23	Voigtlander, Christian B.	Officer	Chief Operating Officer	Direct	Sale	4,959	130.00	$644,670.00	4,903	4
2025-05-21	Voigtlander, Christian B.	Officer	Chief Operating Officer	Direct	Sale	4,917	133.00	$653,961.00	3,711	4
2025-05-19	Finney, Elisha W	Director	-	Direct	Sale	600	138.92	$83,352.00	3,252	4
2025-05-19	Voigtlander, Christian B.	Officer	Chief Operating Officer	Direct	Sale	5,555	138.00	$766,590.00	2,389	4
2025-05-15	Voigtlander, Christian B.	Officer	Chief Operating Officer	Direct	Sale	5,555	135.55	$752,980.25	2,389	4
2025-05-15	Sousa, Ben	Officer	Chief Information Officer	Direct	Sale	2,000	137.36	$274,720.00	479	4
2025-05-13	Greenberg, David C.	Director	-	Direct	Sale	1,942	143.66	$278,987.72	6,760	4
2025-01-02	Jain, Vivek	Director,Officer	Chairman and CEO	Direct	Sale	1,373	155.48	$213,474.04	104,593	4
2024-12-06	Woolson, Daniel	Officer	VP, GM-Infusion Capital	Direct	Sale	2,241	156.25	$350,156.25	10,866	4
2024-12-02	Jain, Vivek	Director,Officer	Chairman and CEO	Direct	Sale	12,000	163.14	$1,957,680.00	104,593	4
2024-11-27	Greenberg, David C.	Director	-	Direct	Sale	972	158.11	$153,682.92	5,037	4
2024-11-27	Voigtlander, Christian B.	Officer	Chief Operating Officer	Direct	Sale	1,430	158.00	$225,940.00	0	4
2024-11-26	Voigtlander, Christian B.	Officer	Chief Operating Officer	Direct	Sale	7,719	159.59	$1,231,875.21	0	4
2024-11-01	Jain, Vivek	Director,Officer	Chairman and CEO	Direct	Sale	12,000	172.26	$2,067,120.00	104,593	4
2024-10-01	Jain, Vivek	Director,Officer	Chairman and CEO	Direct	Sale	12,000	178.91	$2,146,920.00	104,593	4
2024-09-03	Jain, Vivek	Director,Officer	Chairman and CEO	Direct	Sale	12,000	163.45	$1,961,400.00	104,593	4
2024-08-30	Woolson, Daniel	Officer	VP, GM-Infusion Capital	Direct	Sale	2,502	163.22	$408,376.44	13,107	4
2024-08-16	Jain, Vivek	Director,Officer	Chairman and CEO	Direct	Sale	12,000	156.04	$1,872,480.00	104,593	4
2024-08-08	Sanzone, Virginia Ruth	Officer	VP, General Counsel	Direct	Sale	2,050	144.11	$295,425.50	4,482	4
2024-05-30	Voigtlander, Christian B.	Officer	Chief Operating Officer	Direct	Sale	12,539	104.17	$1,306,187.63	0	4
2024-05-16	Finney, Elisha W	Director	-	Direct	Sale	300	104.95	$31,485.00	2,129	4
2024-05-10	Sousa, Ben	Officer	Chief Information Officer	Direct	Sale	2,000	105.55	$211,100.00	1,319	4
2024-03-15	Woolson, Daniel	Officer	VP, GM-Infusion Capital	Direct	Sale	791	98.27	$77,731.57	13,980	4
2024-03-14	Lopez, George A	Director	-	Indirect	Sale	7,978	101.87	$812,718.86	877,343	4
2024-03-12	Lopez, George A	Director	-	Indirect	Sale	1,522	101.51	$154,498.22	885,321	4/A
2024-03-11	Lopez, George A	Director	-	Direct	Sale	1,890	104.22	$196,975.80	317,753	4
2024-03-08	Lopez, George A	Director	-	Direct	Sale	15,372	105.94	$1,628,509.68	319,643	4
2024-03-08	Sanzone, Virginia Ruth	Officer	VP, General Counsel	Direct	Sale	3,300	104.57	$345,081.00	4,771	4
2024-03-04	Voigtlander, Christian B.	Officer	Chief Operating Officer	Direct	Sale	13,603	107.56	$1,463,138.68	0	4
2024-02-29	Smiths, Group Plc	Other	-	Indirect	Sale	830,000	106.08	$88,046,400.00	1,670,000	4
2024-02-29	Smiths, Group Internation…	Other	-	Direct	Sale	830,000	106.08	$88,046,400.00	1,670,000	4
2023-12-01	Woolson, Daniel	Officer	VP, GM-Infusion Capital	Direct	Sale	1,729	88.03	$152,203.87	9,877	4
2023-09-08	Voigtlander, Christian B.	Officer	Chief Operating Officer	Direct	Sale	6,850	129.30	$885,705.00	13,603	4
2023-07-12	Jain, Vivek	Director,Officer	Chairman and CEO	Direct	Sale	30,000	180.02	$5,400,600.00	23,677	4
2023-06-14	Jain, Vivek	Director,Officer	Chairman and CEO	Direct	Sale	30,000	190.21	$5,706,300.00	23,677	4
2023-06-07	Finney, Elisha W	Director	-	Direct	Sale	194	190.41	$36,939.54	1,481	4
Additional insider transactions are for subscribers only. Unlock the complete Form 4 filing history Start 7-day free trial

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Institutional Ownership

No data available for chart

2026-03-31

96.53%

Inst. Shares: 23,905,549

Shares Outstanding: 24,764,000

2025-12-31

102.54%

Inst. Shares: 25,264,776

Shares Outstanding: 24,640,000

2025-09-30

103.94%

Inst. Shares: 25,658,480

Shares Outstanding: 24,686,000

2025-06-30

100.07%

Inst. Shares: 24,661,088

Shares Outstanding: 24,645,000

2025-03-31

97.57%

Inst. Shares: 23,942,509

Shares Outstanding: 24,539,000

Date	Institutional Shares Owned	Shares Outstanding	Institutional Ownership %
2026-03-31	23,905,549	24,764,000	96.53%
2025-12-31	25,264,776	24,640,000	102.54%
2025-09-30	25,658,480	24,686,000	103.94%
2025-06-30	24,661,088	24,645,000	100.07%
2025-03-31	23,942,509	24,539,000	97.57%
2024-12-31	23,671,237	24,388,000	97.06%
2024-09-30	23,524,672	24,438,000	96.26%
2024-06-30	23,017,223	24,393,000	94.36%
2024-03-31	21,709,957	24,222,000	89.63%
2023-12-31	20,550,411	24,091,000	85.30%
2023-09-30	19,164,157	24,132,000	79.41%
2023-06-30	18,835,444	24,075,000	78.24%
Additional institutional holders are for subscribers only. Unlock the complete Form 13F ownership history Start 7-day free trial

ICU MEDICAL INC/DE (ICUI) — SEC Financial Statements & Analysis

ICU MEDICAL INC/DE (ICUI) is a surgical & medical instruments & apparatus company, incorporated in DE. ICU MEDICAL INC/DE trades on Nasdaq as: ICUI. Based on its latest SEC filing (Form 10-Q, period ending 2026-06-30), ICU MEDICAL INC/DE reported a -8.97% year-over-year revenue growth, a Gross Profit Margin of 39.13% (TTM), a Debt-to-Equity ratio of 0.23x, a Price-to-Sales (P/S) ratio of 1.70x (TTM), a Price-to-Book (P/B) ratio of 1.70x (TTM), at a market cap of $3.67B. Figures below are sourced from SEC EDGAR, as-filed.

Net Revenue TTM Growth 1Y: -8.97%
Gross Profit Margin TTM: 39.13%
Debt To Equity: 0.23x
P/S TTM: 1.70x
P/B TTM: 1.70x
Market Cap: $3.67B

Data as of 2026-06-30 · Source: SEC EDGAR

Frequently Asked Questions

What industry is ICU MEDICAL INC/DE in?

ICU MEDICAL INC/DE (ICUI) operates in the Surgical & Medical Instruments & Apparatus industry.

What is ICUI's market cap?

ICU MEDICAL INC/DE (ICUI) has a market capitalization of $3.67B as of 2026-06-30.

What is ICUI's P/E ratio?

ICU MEDICAL INC/DE (ICUI)'s trailing twelve month P/E ratio is 121.81x as of 2026-06-30.

What exchange does ICUI trade on?

ICU MEDICAL INC/DE (ICUI) trades on the Nasdaq.

Where is ICU MEDICAL INC/DE incorporated?

ICU MEDICAL INC/DE is incorporated in DE.